Press Release

Dimension Bio Reports New Preclinical Results Advancing BioNidum™ Platform Toward Restorative Treatment for Liver Failure at AASLD 2025

  • Showcases robust hepatocyte viability, metabolic activity, and vascular integration in subcutaneous 3D-printed implants

  • Highlights survival improvement in preclinical disease models of liver failure, outperforming hydrogel-based delivery systems

  • Supports potential for a minimally invasive, cell-based therapy to address liver failure


CHICAGO, Illinois, USA - November 5, 2025 - Dimension Bio, a biotechnology company developing regenerative therapeutics, today announces the presentation of new data on its liver cell replacement therapy at the upcoming American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025 taking place in Washington D.C., between 7-11 November 2025.

The presentation highlights preclinical studies evaluating Dimension’s BioNidum™ cell delivery and support system for subcutaneous hepatocyte delivery. The data show long-term hepatocyte survival, sustained albumin production, and dense vascularization - outperforming hydrogel-based approaches in maintaining cell function and integration in vivo. In mouse models of liver failure, implants delivered survival improvements exceeding 70% compared to controls.

“Our BioNidum™ platform is redefining how therapeutic cells can be delivered and maintained within the body,” said Caralynn Nowinski Collens, MD, Co-Founder and Chief Executive Officer of Dimension Bio. “These data provide strong validation for our approach to restoring hepatic function through engineered tissue therapeutics. We see this as an important step toward a much-needed treatment for patients facing liver failure.”

Presentation Details:

Title: Treatment of Alcoholic Liver Disease and Liver Failure Using a Novel 3D-Printed PLG-Based Implantable Therapy

  • Poster #: 4110

  • Date: November 10, 2025

  • Time: 8:00 AM – 5:00 PM

+ About Dimension Bio

Dimension Bio is a biotechnology company pioneering regenerative therapeutics. We design lifesaving solutions that restore organ function lost to disease, trauma or aging. Our bioinspired cell delivery system, BioNidum™, fuses materials science, 3D-printing, and digital manufacturing to transform cells into implantable, tissue-like therapies.

By providing a three-dimensional architecture that promotes rapid vascularization and seamless tissue integration, our tissue therapeutics create the conditions cells need to survive, function, and persist. The result is a more durable and effective therapeutic response – unlocking the curative potential of cell therapies.

Our lead program targets liver failure, providing immediate supplemental liver function to stabilize patients in crisis. By enabling the native liver to recover, it offers an alternative to transplant and fills a critical gap for those with limited treatment options.